FTV

FortiveC

NYSE / Capital Goods

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$66.00

+8.9% vs current

Most likely

Base case

50%

Probability

Target price

$62.00

+2.3% vs current

B-

Bear case

25%

Probability

Target price

$54.00

-10.9% vs current

AI sentiment snapshot

Latest data as of 2026-05-03

AI commentary

Primary-source tone is positive, but the T+3 read is still mixed. Fortive's April 30, 2026 release showed a solid beat-and-reaffirm quarter, yet Reuters-syndicated coverage emphasized the benefit from extra selling days and unchanged full-year guidance. Using checked price points, the stock moved from an April 29, 2026 close of $61.75 to the May 1, 2026 anchor close of $59.03, a drop of about 4.4% after the print. Because no clear delayed analyst revision wave was confirmed in checked sources by May 3, 2026, this remains more of a cautious monitoring setup than a strong post-earnings momentum call.

RankAlpha Sentiment Codex - 2026-05-03

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-20catalystQ1 beat is being repriced against unchanged full-year guidance [#8-K-2026-04-30]Medium impact

Fortive reported Q1 revenue of $1.069 billion, adjusted EPS of $0.70, core growth of 5.3%, and said FY2026 adjusted EPS remains $2.90-$3.00 while trending toward the upper half; the release also noted an approximately 150 bps selling-day benefit, which helps explain why a beat did not force a cleaner rerating. Reuters-syndicated coverage reviewed after the print cited $0.64 consensus adjusted EPS versus the reported $0.70. [#8-K-2026-04-30]

2026-07-31eventNext update must prove growth quality beyond selling days and absorb tariff/financing pressure [#10-Q-2026-04-30]Medium impact

Management flagged expected impact from tariffs and trade policy in the 10-Q risk discussion, while commercial paper rose to $1.241 billion at quarter-end and hospital spending pressures were said to persist in low-temperature sterilization. If the next quarter does not show clean organic follow-through without calendar help, the stock could remain range-bound or de-rate. [#10-Q-2026-04-30]

2026-07-31catalystBuybacks, segment margin improvement, and backlog-like revenue visibility can support a gradual recovery [#10-Q-2026-04-30]Medium impact

The Q1 filing showed 8.9 million shares repurchased for about $500 million at an average price of $56.21, Advanced Healthcare Solutions adjusted EBITDA margin up to 25.7% from 23.6%, and remaining performance obligations of $839.9 million, with most expected to convert over the next two to four years. That mix supports a steady execution case even if the near-term rerating stays muted. [#10-Q-2026-04-30]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-03 • Updated nightlySource: Internal modelMethodology